US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...

Otitis externa is one of the most common conditions clinicians encounter, particularly in dogs with allergic skin disease.

Sciences announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81%, ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

Livdelzi Reduced Pruritus Severity in PBC Participants and Led to Near Resolution of Itch in 27% of Participants with ...

According to dermatologist and skincare brand founder Dr. Vanita Rattan, though, I’m not alone (’tis the season, apparently).

Mirum Pharmaceuticals, Inc. today announced that it will present data at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting®, taking place November 15-19, 2024, in San ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello everyone, and welcome to the Mirum Pharmaceuticals’ Third ...

MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024. Stock rises in pre-market.

Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted ...